Improving Outcomes in OAB: New and Emerging Strategies to Reduce Symptom Burden and Treatment Adverse Effects (CME/CE Webcast)

Activity Description and Purpose

Overactive bladder (OAB) is a common condition that can significantly impair quality of life and carries a substantial personal and societal economic burden. Available evidence indicates that OAB is undertreated and inappropriately treated through the use of antimuscarinic medications in patients with dementia. Current and emerging β3-adrenoceptor agonist therapies may have a better risk:benefit profile. The desired results of this activity are for urologists and other clinicians to improve their diagnosis and treatment of OAB.

Target Audience

This educational activity is intended for urologists, urogynecologists, physician assistants, nurse practitioners, nurses, and other clinicians caring for patients with overactive bladder.

Learning Objectives

After completing this activity, participants will be better able to:

  • Apply efficacy and tolerability clinical data to develop long-term treatment plans for patients with overactive bladder
  • Incorporate medication reviews into patient encounters
  • Compare the data on central nervous system effects of antimuscarinic overactive bladder medications with those of β3-adrenoceptor agonists
  • Describe the pharmacologic, efficacy, safety, and tolerability profiles of new and emerging treatments for overactive bladder
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
10/28/2020
Course expires: 
10/31/2021

Faculty

imageRoger Dmochowski, MD, MMHC, FACS (Chair)
Associate Surgeon in Chief
Professor of Surgery
Professor of Urology
Professor of Obstetrics and Gynecology
Vice Chair, Section of Surgical Sciences
Vanderbilt University Medical Center
Nashville, Tennessee
imageKathleen C. Kobashi, MD, FACS
Head, Section of Urology and Renal Transplantation
Virginia Mason Medical Center
Seattle, Washington

Disclosure Policy

MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.

Disclosures

Faculty

Roger Dmochowski, MD, MMHC, is a medical monitor for BlueWind Medical, Caldera Medical, and Viveve.

Kathleen C. Kobashi, MD, is a consultant for Allergan, Contura Ltd, and Medtronic; is on the speakers bureau for Allergan and Medtronic; and is a contracted researcher for Allergan.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners and Managers

MedEdicus planners and managers have no relevant commercial relationships to disclose.
 

For Physicians:

ACCME Accreditation Statement

image MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Credit Designation Statement

MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses:

Interprofessional Joint Accreditation Statement

image In support of improving patient care, Amedco LLC is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Credit

Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.

Disclosure of Commercial Support

This continuing medical education activity is supported through an educational grant from Urovant Sciences, Inc.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs or devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Urovant Sciences, Inc.

©2020 MedEdicus LLC. 230.1

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.

Clicking Register indicates that you have reviewed the CME/CE information for this activity.

Learning Method and Medium

This educational activity consists of a five (5)-question pretest, a webcast, and five (5) study questions. The participant should, in order, read the learning objectives, complete the pretest, view the webcast, answer all questions in the posttest, and complete the evaluation. To receive credit for this activity, please complete the posttest and evaluation. This educational activity should take a maximum of 1.0 hour to complete.